Klinik für Psychiatrie und Psychotherapie / Forschung / Drittmittelprojekte / Prof. Dr. med. Martin Walter - Drittmittelprojekte / Abgeschlossen
Abgeschlossene Drittmittelprojekte Prof. M. Walter
DFG:
- Neuronal Mechanisms of Motivated Behavior - Modulation of excitation/inhibition balance by NMDA receptor antagonism in depression; DFG-CRC779; CRC779-A06
- Untersuchung glutamaterger Störungen bei depressiven Patienten anhand STEAM MRS im Hochmagnetfeld; DFG; SFB779-TPA 6; WA 2673/3-1;
- Stratification and Augmentation of EEG-Neurofeedback in MDD by Monitoring of Dynamic Brain States via Simultaneous Electronencephalography and Magnetci Resonance (EEG-fMRI); DFG;
- Ketamin in therapieresistenter Depresssion; DFG; WA 2673/4-1
BMBF:
(siehe "Aktuelle Drittmittelprojekte")
EU:
- FAT4BRAIN: Networking for excellence in functional pharmacology to study the role of fatty acid metabolism in neurological disorders; EU H2020-WIDESPREAD-2018-2020
- ERA Net – SuppHab: Improvement of treatment resistant depression by suppression of lateral habenula activity
- SyBil-AA: Systems Biology in Alcohol Addiction; EU grant H2020, ID: 668863
- Multimodal Imaging for Correlates of Abnormal Glutamatergic and GABAergic Neurotransmission in MDD Patients, Marie Curie Initial Training Network, r’BIRTH consortium
TMWWDG:
(siehe "Aktuelle Drittmittelprojekte")
Industrie:
- Auftragsforschung Novartis Pharma GmbH (01.07.2021 - 01.12.2023; 112.600,00 €)
- ESCAPE-TRD: A randomized, open-label, rater-blinded, active-controlled, international, multicenter study to evaluate the efficacy, safety, and tolerability of flexibly dosed esketamine nasal spray compared with quetiapine extended-release in adult and elderly participants with treatment-resistant major depressive disorder who are continuing a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor; Janssen-Cilag GmbH; FKZ: 54135419TRD3013
- KET01-02